COVID-19 the Tipping Point for Decentralized Clinical Trials

OracleThe COVID-19 pandemic has disrupted clinical operations and accelerated much-needed change, according to a new survey conducted by Informa Pharma Intelligence on behalf of Oracle Health Sciences. With patients unable to physically visit clinical trial sites, 76% of survey respondents noted that the pandemic sped their adoption of decentralized clinical trial methods. The same percentage (76%) reported at least some of their trials have already been decentralized, and 38% indicated more than half are decentralized. But despite this momentum, respondents said concerns remain around decentralized trial data collection and quality, as well as regulatory guidance.

In regards to ongoing clinical trials, survey respondents said COVID-19 has caused longer enrollment times (49%), amended protocols (45%), and paused protocols (41%).

"The pandemic will have a profound and lasting effect on clinical trials," said Henry McNamara, senior vice president and general manager, Oracle Health Sciences. "The survey results illustrate how quickly the industry has pivoted and adopted new approaches, such as decentralized clinical trial methods, to keep clinical research going in these unprecedented times. Fortunately, our technology supports this change today and is designed to carry the industry forward."

The Accelerated Evolution of Clinical Trials in a Pandemic Environment survey, which was conducted from September 21 through November 11, 2020, gathered data from 252 respondents representing professionals from biopharmaceutical companies, CROs, and medical device companies involved in the operation and management of clinical trials. The respondents were located primarily in North America and Europe, with some representation from the Asia Pacific and the rest of the world.

Decentralized Trials: Opportunities and Challenges

In moving to decentralized clinical trials, the most common steps taken by respondents are the adoption of patient-facing technologies or alternatives (64%) and protocol redesign (63%), followed by the adoption of investigator-facing technologies or alternatives (53%).

When asked about the challenges of adopting decentralized trial methods, patient care and data issues topped the list. Survey respondents cited patient monitoring and engagement (59%) as the top challenge, followed by ensuring data reliability and quality (50%) and data collection (45%).

With the shift to decentralized clinical trials comes the introduction of wearables, remote patient monitoring, and the associated need for remote data collection. According to the survey results, 67% of respondents have already implemented remote data collection into their trials, primarily through the implementation of patient apps (57%), ePRO (49%), and wearables/devices (45%).

Specifically, as it relates to wearables and remote monitoring technology, respondents’ top concerns with this shift are data requiring a different approach to review, manage, and interpret (49%), expense (46%), and complicated regulatory considerations (42%).

Additionally, respondents were universally concerned with the clinical data gathered from wearables and remote monitoring technology. The top issues noted were in regards to remote data collection, including data quality (57%), data protection/privacy (40%), and lack of standardization in data (36%).

However, these concerns were balanced with an expectation that using wearables and remote monitoring technology would increase patient convenience (64%), provide a more comprehensive supply of real-time data and insights (52%), and result in savings in terms of time and resources for site staff (45%).

"There's no question organizations have adapted to decentralized trials very quickly, but there are many advantages and disadvantages to address," McNamara added. "It's clear with the right regulatory guidance, processes, and technologies in place, the shift can be advantageous to patients, sites, and sponsors moving forward. In the end, it’s really about serving the needs of the individuals participating in the trials, who are donating their time and their bodies to research for the advancement of medicine."

Industry Divided on Regulatory Guidance

While the move to decentralize clinical trials is well underway, the survey revealed that the industry is divided regarding the clarity of current regulatory guidance surrounding decentralized trials and data collection, indicating a need for improvement. When asked if the current regulatory guidance was clear, 52% said "yes," and 48% said "no."

Additionally, from the 24% of respondents who reported that the pandemic had not accelerated their adoption of decentralized clinical trials, regulatory concerns (42%) were a top reason.

"With 48% of respondents indicating that current regulatory guidance surrounding decentralized trials and data collection is not clear, there is an opportunity for the industry to work with the regulators to help bring the clarity needed for sponsors to embrace this emerging model," noted McNamara.

Additional Information

To read the full research report, please visit:
https://go.oracle.com/researchacceleratedtrials?elqCampaignId=257896

To learn more about how Clinical One supports decentralized clinical trials, please visit:
https://www.oracle.com/a/ocom/docs/industries/life-sciences/clinical-one-overview-solution-brief.pdf

About Oracle Health Sciences

As a leader in Life Sciences cloud technology, Oracle Health Sciences’ Clinical One and Safety One are trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance. With over 20 years’ experience, Oracle Health Sciences is committed to supporting clinical development, delivering innovation to accelerate advancements, and empowering the Life Sciences industry to improve patient outcomes. Oracle Health Sciences. For life.

About Oracle

The Oracle Cloud offers a complete suite of integrated applications for Sales, Service, Marketing, Human Resources, Finance, Supply Chain and Manufacturing, plus Highly Automated and Secure Generation 2 Infrastructure featuring the Oracle Autonomous Database.

Most Popular Now

Personalized Breast Cancer Prevention No…

A new telemedicine service for personalised breast cancer prevention has launched at preventcancer.co.uk. It allows women aged 30 to 75 across the UK to understand their risk of developing breast...

New App may Help Caregivers of People Ge…

A new study by investigators from Mass General Brigham showed that a new app they created can help improve the quality of life for caregivers of patients undergoing bone marrow...

An App to Detect Heart Attacks and Strok…

A potentially lifesaving new smartphone app can help people determine if they are suffering heart attacks or strokes and should seek medical attention, a clinical study suggests. The ECHAS app (Emergency...

A Machine Learning Tool for Diagnosing, …

Scientists aiming to advance cancer diagnostics have developed a machine learning tool that is able to identify metabolism-related molecular profile differences between patients with colorectal cancer and healthy people. The analysis...

Fine-Tuned LLMs Boost Error Detection in…

A type of artificial intelligence (AI) called fine-tuned large language models (LLMs) greatly enhances error detection in radiology reports, according to a new study published in Radiology, a journal of...

DeepSeek-R1 Offers Promising Potential t…

A joint research team from The Hong Kong University of Science and Technology and The Hong Kong University of Science and Technology (Guangzhou) has published a perspective article in MedComm...

Deep Learning can Predict Lung Cancer Ri…

A deep learning model was able to predict future lung cancer risk from a single low-dose chest CT scan, according to new research published at the ATS 2025 International Conference...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...